VCANBIO CELL & GENE ENGINEERING CORP., LTD

Andere Sprachen Vcanbio Cell & Gene Engineering Corp., Ltd

Aktien

A0M3LR

CNE000000545

600645

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 12.06.2024			% 5 Tage	% 1. Jan.
17,08 ^CNY	+0,89 %		-1,73 %	-15,74 %

25.04.	Vcanbio Cell & Gene Engineering Corp., Ltd meldet Ergebnis für das Gesamtjahr bis zum 31. Dezember 2023	CI
25.04.	Vcanbio Cell & Gene Engineering Corp., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25.04.
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	20.04.
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	18.04.
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	02.04.
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	19.02.
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	17.02.
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	26.12.
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	08.11.
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27.10.23
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	16.10.23
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	29.09.23
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index	18.09.23
MET Group signs energy supply deal with Commonwealth LNG	04.09.23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	24.08.23
Vcanbio Cell & Gene’s Pulmonary Fibrosis Treatment Wins Orphan Drug Designation in US	14.08.23
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	08.06.23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25.04.23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	25.04.23
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	13.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vcanbio Cell & Gene Engineering Corp., Ltd

Aktien

A0M3LR

CNE000000545

600645

Andere Sprachen

Filter